Erratum

Efficacy and Tolerability of Buccal Buprenorphine in Opioid-Experienced Patients With Moderate to Severe Chronic Low Back Pain: Results of a Phase 3, Enriched Enrollment, Randomized Withdrawal Study: Erratum.

The authors would like to draw your attention to the reporting of incorrect morphine sulfate equivalent (MSE) dose ranges that were published in the Patient disposition section of the Results. MSE dose ranges that were reported in μg amounts should have been reported as mg amounts as follows:

In the double-blind treatment phase, 254 patients were randomized to the BBUP group: 221 (87.0%) on <80 mg MSE, 26 (10.2%) on 80 to 120 mg MSE, and 7 (2.8%) on >120 mg MSE In total, 257 patients were randomized to the placebo group, but 1 did not receive double-blind study medication. Of the 256 remaining placebo patients, 216 (84.4%) were on <80 mg MSE, 33 (12.9%) on 80 to 120 mg MSE, and 7 (2.7%) on >120 mg MSE.